Adlai Nortye Ltd. (NASDAQ:ANL) Sees Large Decline in Short Interest

Adlai Nortye Ltd. (NASDAQ:ANL) was the target of a significant decrease in short interest in the month of October. As of October 31st, there was short interest totalling 3,100 shares, a decrease of 27.9% from the October 15th total of 4,300 shares. Based on an average trading volume of 14,400 shares, the days-to-cover ratio is currently 0.2 days.

Adlai Nortye Price Performance

Adlai Nortye stock traded up $0.07 during trading hours on Friday, hitting $3.34. The company had a trading volume of 18,978 shares, compared to its average volume of 11,677. The company has a 50-day moving average price of $2.18 and a two-hundred day moving average price of $4.51. Adlai Nortye has a 1 year low of $1.85 and a 1 year high of $17.48.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “buy” rating and issued a $9.00 price target on shares of Adlai Nortye in a report on Monday.

About Adlai Nortye

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.